Todd Bazemore Sells 47,768 Shares of KALA BIO (NASDAQ:KALA) Stock

KALA BIO, Inc. (NASDAQ:KALA) Director Todd Bazemore sold 47,768 shares of the company’s stock in a transaction on Wednesday, October 22nd. The stock was sold at an average price of $0.83, for a total transaction of $39,647.44. Following the transaction, the director owned 35,932 shares in the company, valued at approximately $29,823.56. The trade was a 57.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

KALA BIO Stock Performance

KALA opened at $0.80 on Friday. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 3.19. The company’s fifty day moving average price is $9.01 and its two-hundred day moving average price is $6.29. KALA BIO, Inc. has a 1-year low of $0.77 and a 1-year high of $20.60. The company has a market cap of $5.59 million, a price-to-earnings ratio of -0.12 and a beta of -2.10.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Friday, August 8th. The company reported ($1.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.82) by $0.11. On average, analysts expect that KALA BIO, Inc. will post -10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on KALA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of KALA BIO in a research note on Wednesday, October 8th. Oppenheimer upped their target price on shares of KALA BIO from $15.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. Wall Street Zen lowered shares of KALA BIO from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. LADENBURG THALM/SH SH lowered shares of KALA BIO from a “buy” rating to a “neutral” rating in a research report on Monday, September 29th. Finally, Mizuho set a $1.50 price target on shares of KALA BIO in a research report on Tuesday, September 30th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $20.38.

Institutional Investors Weigh In On KALA BIO

Several institutional investors have recently added to or reduced their stakes in the business. AIGH Capital Management LLC lifted its holdings in KALA BIO by 52.8% during the second quarter. AIGH Capital Management LLC now owns 300,000 shares of the company’s stock valued at $1,428,000 after purchasing an additional 103,650 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in KALA BIO by 35.7% during the first quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company’s stock valued at $1,713,000 after purchasing an additional 78,582 shares during the last quarter. Woodline Partners LP purchased a new stake in KALA BIO during the first quarter valued at about $1,483,000. Geode Capital Management LLC lifted its holdings in KALA BIO by 2.8% during the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after purchasing an additional 1,534 shares during the last quarter. Finally, Readystate Asset Management LP purchased a new stake in KALA BIO during the first quarter valued at about $243,000. 24.61% of the stock is owned by hedge funds and other institutional investors.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.